Novartis Ag Stock News

The FDA approves Novartis' (NVS) Cosentyx for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug Novartis AG (NYSE: NVS ) announced the U.S. Food and Drug Administration has approved Cosentyx for the treatment of active enthesitis-related arthritis in patients four years and older, and active psoriatic arthritis in patients two years and older. Cosentyx is now the first biologic indicated for ERA and the only biologic treatment approved for both ERA and PsA in pediatric patients in the U.S., the company said. Separately, the company announced FDA approval of Leqvio, the first and only small interfering RNA therapy to lower low-density lipoprotein cholesterol, with two doses a year, after an initial dose and one at three months. Leqvio has been licensed from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) by the Medicines Company, which has since then been acquired by Novartis. Novartis shares were up 0.54% at $86.78 in premarket trading.

According to the report, The global Nasal Drug Delivery Technology market size is expected to reach $106.70 Billion by 2028 growing at the CAGR of 7.09% from 2021 to 2028. The major factor driving the growth of the Nasal Drug

New Research Study ""Auto Injectors Market 2021 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook"" has been added to Coherent Market insight The global Auto Injectors market was valued at US$ 1,904.1 Mn

Herpes labialis (oral herpes) is a type of herpes simplex that occurs on the lips. That is, it is an infection caused by the herpes simplex virus (HSV). The outbreak usually causes small blisters or ulcers around the mouth. Ulcers

The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) for active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patien

The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C).  Leqvio is indicated in the U.S. as an adjunct to diet a

The North America Hematuria Treatment Market is projected to reach US$ 419.7 million by 2028 from US$ 351.6 million in 2021; it is anticipated to grow at a CAGR of 2.6% from 2021 to 2028. Hematuria is a medical condition where

The US Meals and Drug Administration (FDA) has accredited inclisiran (Leqvio) as an adjunct to statins for extra reduction of LDL ldl cholesterol stages, the drug''s developer, Novartis, presented at present time. The first-in-class little interfering RNA (siRNA) agent is moreover original among gaze drug therapies for its administration by injection within the origin, at

New approvals are based on JUNIPERA trial data showing Cosentyx (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both

Basel, December 22 , 2021 Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older 1 . Cosentyx is now the first biologic indicated for ERA, and the only biologic treatment approved for both ERA and PsA in pediatric patients in the US. These are the second and third approvals for Cosentyx in a pediatric population in the US, and Cosentyx now has a total of five indications across rheumatology and dermatology 1 .

Novartis AG (NYSE: NVS) announced it is buying Gyroscope. These are the details.

The prize Novartis has its eyes on is, well, eyes. The Swiss healthcare giant announced Wednesday it's buying British biotech Gyroscope.

Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.